ReviewMedical microbiology and immunology2009
Buruli ulcer disease: prospects for a vaccine.
Review in Medical microbiology and immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 74 citations in OpenAlex.
- Antimicrobial resistant bacteria isolated from Buruli ulcer lesions in Ghana.PLoS neglected tropical diseases · 2025Article
- A composite subunit vaccine confers full protection against Buruli ulcer disease in the mouse footpad model of Mycobacterium ulcerans infection.PLoS neglected tropical diseases · 2025Article
- In silico formulation of a next-generation multiepitope vaccine for use as a prophylactic candidate against Crimean-Congo hemorrhagic fever.BMC medicine · 2023Article
- Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches.Cancer immunology, immunotherapy : CII · 2022Article
- Natural-Product-Based Solutions for Tropical Infectious Diseases.Clinical microbiology reviews · 2021Review
- Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.PLoS neglected tropical diseases · 2016Article
- Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.PLoS neglected tropical diseases · 2016Article
- Detection of Mycobacterium ulcerans by real-time PCR with improved primers.Tropical medicine and health · 2016Article
- Spontaneous Healing of Mycobacterium ulcerans Lesions in the Guinea Pig Model.PLoS neglected tropical diseases · 2015Article
- Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.PLoS neglected tropical diseases · 2015Article
- Recent publications in medical microbiology and immunology: a retrospective.Medical microbiology and immunology · 2012Review
- Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy--a case report from Togo.PLoS neglected tropical diseases · 2012Article
- Article
- Help-seeking for pre-ulcer and ulcer conditions of Mycobacterium ulcerans disease (Buruli ulcer) in Ghana.The American journal of tropical medicine and hygiene · 2011Article
- Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?Future microbiology · 2011Review
- Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?PLoS neglected tropical diseases · 2011Article
- "Manifesto" for advancing the control and elimination of neglected tropical diseases.PLoS neglected tropical diseases · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 16 institutions in 14 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is a neglected bacterial infection of the poor in remote rural areas, mostly affecting children. BUD is a mutilating disease leading to severe disability; it is the third most common mycobacterial infection in immunocompetent people after tuberculosis and leprosy. It is most endemic in West Africa, but cases have been reported from more than 30 countries. Treatment with antibiotics is possible, long-lasting and requires injections; there are cases of treatment failures, and the disease is prone to resistance. A vaccine against M. ulcerans would protect persons at risk in highly endemic areas, and could be used as a therapeutic vaccine to shorten the duration of treatment and prevent relapses. There is considerable evidence supporting the notion that generation of a vaccine is feasible. This article reviews the present state of the art with special emphasis on the immunology of the infection and the prospects for development of a vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.